Therapy Areas: Cardiovascular
ProtoKinetix Partners with The University of British Columbia to Research Effect of AAGP on Monoclonal Antibody Production and Bone Marrow Recovery
12 January 2018 - - Marietta, Ohio-based molecular biotechnology company ProtoKinetix, Inc. (OTCQB: PKTX) has entered into a research agreement with The University of British Columbia (UBC), under the direction of principal investigator Dr. Kelly McNagny, Professor, Faculty of Medicine, Department of Medical Genetics, the company said.
This research agreement is to test and determine the effect of AAGP on monoclonal antibody production and bone marrow recovery.
UBC's antibody lab will test whether AAGP enhances the production of monoclonal antibodies from cell lines, an important manufacturing issue for current immunotherapies.
UBC will also test whether AAGP enhances the survival/efficacy of engraftment of hematopoietic stem cells, a technical hurdle in cell based therapies for bone marrow transplantation and cancer therapy.
The goal will be to determine whether AAGP enhances the ex vivo survival and maintenance of multipotent potential in a way that could be used to enhance bone marrow transplantation.
ProtoKinetix has developed and patented a family of hyper stable, potent glycopeptides that enhance both engraftment and protection of transplanted cells used in regenerative medicine. The University of Alberta has begun Phase 1 human clinical trials.
Additional studies will be expanded to include whole organ transplantation and all therapies that are being developed globally to date including diabetes, retinal degeneration, cardiac repair, and other degenerative conditions.
In addition, The company is studying the potential impact on several cancer therapies.


Related Headlines